IP Library › Granted Patent US 7,528,226
Granted Patent B2
US 7,528,226 · App. 11/401,744 · Granted May 5, 2009

TGFβ1-inhibitor peptides

Assignee: Rojecto de Biomedicina Cima S.L.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,528,226
App. No.
11/401,744
Granted
May 5, 2009
Kind
B2
Abstract

Antagonistic synthetic peptides, obtained from TGFβ1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment of liver diseases and more concretely in cases of fibrosis. The said compositions can optionally include mimotopes of the said active peptides.

Claims (13)

1. An isolated peptide that consists of 15 or fewer amino acids and inhibits TGF-beta 1 activity, wherein the isolated peptide is selected from the group consisting of: (a) a first peptide consisting of SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147 or SEQ ID NO: 61 and (b) a second peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO 2, SEQ ID NO: 6, and SEQ ID NO: 7.

2. The isolated peptide according to claim 1 , wherein the isolated peptide is soluble in buffered RPMI medium.

3. The isolated peptide according to claim 1 , wherein the isolated peptide consists of the second peptide which comprises the amino acid sequence of SEQ ID NO: 2.

4. The isolated peptide according to claim 1 , wherein the isolated peptide consists of the second peptide which comprises the amino acid sequence of SEQ ID NO: 6.

5. The isolated peptide according to claim 1 , wherein the isolated peptide consists of the second peptide which comprises the amino acid sequence of SEQ ID NO: 7.

6. A composition comprising the isolated peptide of claim 3 in an amount effective to inhibit TGF-beta 1 activity in a mammal.

7. A composition comprising the isolated peptide of claim 4 in an amount effective to inhibit TGF-beta 1 activity in a mammal.

8. A composition comprising the isolated peptide of claim 5 in an amount effective to inhibit TGF-beta 1 activity in a mammal.

9. The isolated peptide according to claim 1 , wherein the isolated peptide consists of the first peptide, said first peptide consisting of SEQ ID NO: 61.

10. The isolated peptide according to claim 1 , wherein the isolated peptide consists of the first peptide, said first peptide consisting of SEQ ID NO: 144.

11. The isolated peptide according to claim 1 , wherein the isolated peptide consists of the first peptide, said first peptide consisting of SEQ ID NO: 145.

12. The isolated peptide according to claim 1 , wherein the isolated peptide consists of the first peptide, said first peptide consisting of SEQ ID NO: 146.

13. The isolated peptide according to claim 1 , wherein the isolated peptide consists of the first peptide, said first peptide consisting of SEQ ID NO: 147.

Priority Claims (1)
ES 9802465 · Nov 24, 1998 · national
Continuity (2)
Continuation 0983125300
Related Publication 20070014767A1 · Jan 18, 2007